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ABSTRACT 
INTRODUCTION: While improvements have been made in reducing breast cancer 
incidence and mortality over the past twenty years, disparities in breast cancer mortality 
remain. Understanding systematic differences in breast cancer treatment and quality of 
care remain at the epicenter of understanding breast cancer disparities. Needle biopsy is a 
less invasive and less expensive diagnostic test for breast cancer (as compared to 
excisional biopsy) and permits diagnosis while avoiding unnecessary surgery. This study 
was conducted to 1) examine how the National Quality Forum (NQF)-endorsed needle 
biopsy utilization measure varies geographically (i.e. state and region) and 2) determine 
the patient- and/or health system-level factors that predict guideline concordance among 
women with breast cancer who received treatment at Commission on Cancer-accredited 
facilities. METHODS: Patients who received a breast cancer diagnosis from January 1, 
2004 to December 31, 2015 were selected from the National Cancer Database, which 
captures information from over 70% of newly diagnosed breast cancers in the United 
States. Patients whose breast cancer was diagnosed by needle biopsy were compared with 
patients who did not receive needle biopsy to diagnose their breast cancer by analyzing 
patient-, tumor-, and facility-level factors. Generalized linear mixed modeling was used 
to identify important predictors of needle biopsy receipt. RESULTS: Of 1,362,417 
patients, 78.8% had received needle biopsy to diagnose their breast cancer. Patients were 
significantly more likely to undergo needle biopsy if they were nonwhite, had health 
iv 
insurance coverage through Medicaid or were uninsured/unknown form of insurance, had 
a comorbidity index score of 0, and were diagnosed with T3 lesions. Facility-level 
predictors of needle biopsy receipt were being diagnosed at a facility in the New England 
census region  and being diagnosed at a medium/high case volume facility. Patients who 
resided in metropolitan areas of 1 million people or more had increased odds of receiving 
a needle biopsy as compared to individuals from smaller urban and rural areas. 
CONCLUSION: This study suggests the significant impact that individual- and facility-
level predictors have in reducing health inequalities in breast cancer to support the 
optimization of facility access,  thus reducing breast cancer treatment disparities across 
patient populations.
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CHAPTER 1 
INTRODUCTION 
 
Breast Cancer Burden in the United States 
Breast cancer affects approximately 237,000 women in the United States annually 
(1). Among women, breast cancer is the leading cause of cancer incidence and the 
second-leading cause of cancer deaths in the United States (2). Breast cancer is a disease 
in which abnormal cells in the breast divide uncontrollably. If left untreated, breast 
cancer can spread outside the breast through blood vessels and lymph vessels and 
metastasize to other parts of the body. Breast cancer incidence rates in the U.S. began 
decreasing in 2000 due to advancements in detection through screening leading to 
declining incidence and mortality (3–6).  
Disparities in Breast Cancer Care 
While there has been effort in improving breast cancer prevention and treatment, 
inconsistencies remain within breast cancer care. In 1999, an Institute of Medicine (IOM) 
report articulated that many patients were receiving suboptimal treatment for their cancer. 
For instance, the report identified the lack of adherence to standards for diagnosis, 
inadequate patient counseling regarding treatment options, and underuse of radiation 
therapy and adjuvant chemotherapy after surgery as the main quality issues in breast 
cancer care (7).  The report defined quality cancer care as “providing patients with 
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appropriate services in a technically competent manner, with good communication, 
shared decision making, and cultural sensitivity (7).“ Upon publication of this report, a 
plethora of organizations, including the National Quality Forum (NQF), used the 1999 
report to develop performance measures related to the diagnosis and treatment of various 
cancers, including breast cancer (8). In 1994, 56% of women aged 50 and older had 
received a mammogram to detect breast cancer within the past 2 years. However, due to 
the incorporation of quality standards as a result of the IOM report, the prevalence of 
mammography has increased to 67% for women aged 50 and older as of 2015.  
Studies have shown that socioeconomic, racial, and geospatial disparities exist in 
breast cancer treatment (9–13).  For example, a cross-sectional study reported that 34% 
of black women, and 23% of Hispanic women failed to receive appropriate adjuvant 
therapy as compared to 16% of white women (14). Similarly, in a population-based study 
conducted in Georgia, black women had significantly increased odds of late stage 
diagnosis (OR 2.08, p = 0.0001) and decreased odds of surgery (OR 0.50, p  =0.0001) 
(15). Breast cancer patients often undergo complicated individualized treatment regimens 
involving a multitude of providers and settings of care. Providers face an expanding 
evidence base for treatment and can be limited in their treatment options based on the 
capabilities of their facility or access to technologies. Intervening through the health care 
setting by which breast cancer treatment is received presents feasible opportunities to 
improve cancer treatment across the realm of breast cancer (16).  
Previous studies have identified deficiencies in quality of care for breast cancer 
patients (17,18) but few studies have examined guideline concordance for breast cancer 
patients across large geographic areas and multiple institutions (18–21). Health systems 
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likely contribute to the persistent variation observed across geographic areas in quality of 
care received, and ultimately health disparities (22). Elucidating factors driving breast 
cancer treatment disparities across geographic regions and population subgroups may 
inform interventions targeting modifiable patient- and/or provider-level care 
characteristics. 
Quality of Breast Cancer Care Measurement 
 The NQF was created in 1999 to safeguard and improve patient protections and 
healthcare quality through measurement and reporting. The federal government relies on 
the NQF for evidence-based approaches for integrating new health policies and practices 
as well as evaluating performance of healthcare facilities. The NQF currently endorses 10 
breast cancer treatment quality measures across realms of breast cancer surgery, 
diagnosis, and screening.   
The American Society of Clinical Oncology (ASCO) has developed evidence-
based clinical guidelines to provide physicians with an appropriate method of treatment 
and care. Among these guidelines include those specifically designed for the 
standardization of breast cancer treatment. The American College of Surgeons’ 
Commission on Cancer (CoC), a coalition dedicated to improving survival and quality of 
life for cancer patients through standard-setting and monitoring quality of care, developed 
a similar series of breast cancer treatment quality metrics and submitted these metrics to 
the National Quality Forum. The American Society of Clinical Oncology and the CoC 
provide physicians and researchers with breast cancer treatment metrics endorsed by the 
National Quality Forum.  
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The National Cancer Database (NCDB) sources hospital registry data from more 
than 1,500 CoC-accredited facilities in the U.S. These data, which represent 70% of 
newly diagnosed cancer cases in the U.S., serve as the basis for quality improvement and 
are used to analyze and monitor patients with malignant forms of cancer, their treatment 
and outcomes. The CoC and the NCDB developed the NCDB Quality Reporting Tools to 
provide CoC-accredited cancer programs with the mechanisms needed to evaluate the 
cancer care delivery to their patients. Among these NCDB Quality Reporting Tools 
include the Cancer Program Practice Profile Reports (C3PR). C3PR currently utilizes 
three types of measures in the evaluation of breast cancer treatment: i) accountability 
measures promote improvements in care delivery and demonstrate physician 
accountability and transparency in services provided; ii) quality improvement measures 
function to monitor the need of quality improvement within individual programs; iii) 
surveillance measures used to monitor patters and trends of care while generating 
information for decision making.  
Objective and Research Questions 
 The overall objective of this research is to examine variation in breast cancer 
treatment quality among CoC-accredited facilities using needle biopsy as a quality 
indicator of guideline-concordant breast cancer treatment. The research questions are: 
1. How does needle biopsy receipt vary geographically (e.g. region)? 
2. What patient and/or health system factors predict guideline-concordant needle 
biopsy utilization among women with breast cancer receiving treatment at CoC-
accredited facilities? 
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Significance 
 Despite advances in breast cancer survival, treatment disparities persist for many 
quality indicators including needle biopsy utilization, breast-conserving surgeries, and 
timely use of radiation therapy (23,24). Metrics such as the NQF and CP3R allow for 
hospital performance benchmarking and inform surveillance and quality improvement 
strategies (20). Favorable scores on these metrics are potentially related to favorable 
prognosis among breast cancer patients (25). Additionally, research suggests that care 
quality favorably impacts breast cancer survival (26). While previous studies document 
geographic variation in breast cancer treatment, there is a dearth of information on why 
breast cancer treatment variation exists, as predicted by patient- and health system-level 
factors (21). If we learn why there is geographic variation in breast cancer treatment, 
improvements can be made in resource allocation and health policy decision-making, 
which would lead to increased breast cancer treatment guideline concordance and, in 
turn, improved breast cancer treatment and survival outcomes.
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 MEASURES OF BREAST CANCER TREATMENT QUALITY 
2.1.1 National Quality Forum 
The NQF currently has 6 CoC and American College of Surgeons-endorsed 
measures that assess breast cancer treatment in the existing literature (Table 2.1).  
2.1.2 Annals of Oncology Clinical Practice Guidelines 
The Annals of Oncology Clinical Practice Guidelines were developed in 
accordance with the European Society for Medical Oncology (ESMO) standard operating 
procedures to assess breast cancer treatment. Levels of evidence through studies and 
surveillance and grades of recommendation are incorporated into this set of guidelines 
(26). 
2.2 SOCIODEMOGRAPHIC PREDICTORS OF BREAST CANCER 
TREATMENT QUALITY 
2.2.1 Race 
Race plays a vital role as a predisposing factor in the diagnosis and survival of 
breast cancer (21,26–33). While non-Hispanic white women are more likely to be 
diagnosed with breast cancer, non-Hispanic black women are more likely to die from 
breast cancer (28). Hispanic women experience lower incidence and mortality rates of 
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breast cancer than non-Hispanic white women and non-Hispanic black women (28). 
There are a number of different factors that contribute to racial disparities in breast cancer 
survival and treatment, including the underuse of mammography screening and 
organizational differences within health facilities (11, 29). 
Timely initiation to treatment is associated with increased survival rates among 
women with breast cancer. In a population-based study examining race and treatment 
delay, it was found that African American women experienced greater delay in treatment 
than white women among those who are less than 50 years old (30). More specifically, 
African American women were found to have begun treatment, on average, 6 days later 
after diagnosis than white women (31). Among women who were treated for breast 
cancer with surgery, mean time to surgery was higher in black women (mean 47 days) 
than white women (mean 33 days), further providing evidence that prolonged delays to 
breast cancer surgery exist among minorities (32). 
Studies mentioned in this literature review utilized the NCDB, but a large portion 
of the studies selected to be included in this review of the literature used data from the 
National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) 
Program. In particular, a cross-sectional study conducted in Georgia using SEER data 
examined the outcomes of late stage breast cancer diagnosis by race. In this study, non-
Hispanic black women had significantly increased odds of late stage diagnosis and 
unknown tumor stage, decreased odds of receiving radiation or surgery, and increased 
risk of death following breast cancer diagnosis (15). A similar study conducted using 
SEER-Medicare linked data found racial disparities between black and white women in  
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receiving adjuvant chemotherapy and radiotherapy following breast-conserving surgery. 
According to this cross sectional study, black women with node-positive and node 
negative tumors were less likely (25% and 17%, respectively) to receive chemotherapy 
than white women after adjusting for patient and tumor characteristics (33).  
            The use of adjuvant therapy in the treatment of breast cancer has been widely 
accepted across different diagnostic stages of breast cancer. However, adherence to 
adjuvant therapy plays a vital role in the success of the treatment received. A study, using 
SEER data from 2001 to 2007, examined adjuvant endocrine therapy with chemotherapy 
adherence (evaluated by race). Investigators found that black women had lower initiation 
of adjuvant endocrine therapy (34, 35). Additionally, a cross-sectional study examining 
racial disparities in the adherence of adjuvant treatments for early-stage breast cancer 
found that minority women (defined as non-Hispanic black women and Hispanic women) 
with early-stage breast cancer have nearly double the risk of white women for failing to 
receive necessary adjuvant treatments despite rates of oncologic consultation similar to 
those of white women (14). 
            Several women elect to receive more aggressive forms of breast cancer treatment 
to minimize their risk of developing breast cancer subsequently in the future. The use of 
contralateral prophylactic mastectomy is increasing among women, partially due to 
increased awareness of genetic risks of breast cancer and improved reconstructive 
techniques. In a clinically administered survey issued from 2007-2009, it was found that 
black women were less likely than white women to undergo contralateral prophylactic 
mastectomy after adjustment for clinical factors and family history of breast cancer 
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(36). The findings of this study may be indicative of racial disparities in the patient-
provider continuum. 
            Geography/residential status may be an intrinsic quality of racial disparities 
existing in breast cancer treatment. In a study examining SEER-Medicare data among 
white, black, and Hispanic women aged 66 to 85, investigators found that individuals 
who lived in areas with greater black segregation and greater Hispanic segregation were 
less likely to receive adequate breast cancer care, further contributing to the notion that 
segregation may act as a mediator for the racial disparity in breast cancer treatment (37). 
2.2.2 Age 
 Age is recognized as a risk factor for developing breast cancer. Incidence rates of 
invasive breast cancer incidence increase from ages 40 to 65, but the incidence of breast 
cancer remains steady from age 65 until age 80 when incidence begins to decrease (38). 
These trends in data are likely a result of health initiatives to increase screening 
awareness among women of ages 45 to 50 (39).  
 A study using Surveillance, Epidemiology, and End Results (SEER)-Medicare 
data examined guideline concordance among metastatic breast cancer patients receiving 
systemic therapy in an elderly population (mean age at diagnosis was 76.5 years) (40). It 
was found that the mean age of diagnosis was 78.0 for those untreated versus 76.0 for 
those treated (adjusted ORage continuous/year 1.07, 95% CI: 1.04, 1.11) (40).  The findings of 
this particular study suggest that non-receipt of recommended initial systemic therapy is 
more common among older women (40). Physicians and health policy officials could use 
these data to optimize treatment quality breast cancer-directed care for older populations 
of women with metastatic breast cancer. 
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 A prospective cohort study was conducted in 2015 examining guideline 
concordant breast cancer treatment and individual-level factors among women with 
incident breast cancer in southwest Georgia (41). The results of this study indicated that 
women aged 50-64 years (OR 0.29, 95% CI: 0.15, 0.58) and 65 years and older (OR 0.30, 
95% CI: 0.13, 0.71) were less likely to be guideline-concordant for chemotherapy 
compared to those who are younger than 50 years (41). Additionally, women aged 65 
years and older were less likely to be guideline-concordant for hormonal therapy 
compared to those who are younger than 50 years (OR 0.50, 95% CI: 0.28, 0.90) (41). 
 Early stage breast cancer is typically treated with postoperative radiotherapy. If 
receipt of treatment is guideline concordant, the risk for local recurrence is reduced and 
likelihood of survival is prolonged (41–43). In a population-based study investigating 
patient compliance with radiotherapy after breast-conserving surgery, investigators 
explored age as a predictor of guideline concordance (44). This study found that 
noncompliance was associated with patient age (p < 0.0005) (44). Additionally, 
investigators found that compliance with radiotherapy was statistically higher in patients 
who received adjuvant hormone therapy than in patients who did not receive hormone 
therapy (p < 0.0005) (44). Omission of radiotherapy after breast-conserving surgery in 
patients with early breast cancer may lead to failure to control local tumors, which could 
negatively affect the prognosis of breast cancer patients. 
 In a study examining breast cancer treatment guidelines from 1998 – 2011 among 
breast conserving surgery recipients, it was observed that chemotherapy guideline 
adherence dropped steadily by age (45); 88.5% of women had guideline concordant 
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therapy under the age of 40, 80% in women aged 40-49, 67.7% in women aged 50-69, 
and 28.5% in women who were 70 years or older (45).  
2.2.3 Education/Income 
 Education and income are key components that comprise socioeconomic status. A 
plethora of lifestyle and behavioral factors associated with education level and income 
may influence breast cancer risk, including age at first birth, physical activity, and 
participation in screening programs. Furthermore, factors associated with education and 
income may influence breast cancer survival, including adherence to breast cancer 
treatment guidelines.  
 Current treatment guidelines recommend breast conserving therapy for early stage 
breast cancers. Breast conserving therapy consists of breast conserving surgery followed 
by whole breast radiation therapy, endocrine therapy for women with invasive, hormone 
receptor positive breast cancer, and chemotherapy for patients with axillary lymph node 
positive disease regardless of receptor status. In a study analyzing trends in guideline 
adherence according to socioeconomic status, investigators sought to identify areas of 
improvement in breast conserving therapy (45). Women who belonged in the lowest 
education and income levels (individuals who did not graduate high school; individuals 
earning < $38,000) experienced disparities in breast conserving surgery for the duration 
of the study (45). Among women in the lower education and income levels, endocrine 
therapy guideline adherence rates were 68.5% in 2004-2006, but increased slightly to 
74.8% (45). 
 A similar study conducted in 2012 found that women who resided in high-poverty 
and low-education areas were more likely to not adhere to breast cancer treatment 
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guidelines for chemotherapy (OR 0.77, 95% CI: 0.50, 0.86) (46). In the same study, 
women who reside in low-income areas and received hormonal therapy were less likely 
to receive guideline concordant treatment (OR 0.78, 95% CI: 0.64, 0.96) (46). The 
findings of this study suggest that inequities in breast cancer treatment prevail for women 
of low socioeconomic status, but offer no recommendation for the elimination of such 
inequities. 
2.3 ACCESS TO CARE-RELATED ISSUES  
2.3.1 Insurance Status 
 Current evidence suggests that disparities in insurance coverage among women 
with breast cancer is a predictor of receiving appropriate treatment (47, 48). Economic 
barriers experienced by women with a breast cancer diagnosis may contribute to worse 
outcomes for treatment, prognosis, and mortality (49, 50). Public screening programs 
catered towards women lacking insurance or women relying on public insurance may 
eliminate the disparities experienced among women who lack private insurance or who 
are not eligible for Medicare. 
 A significant predictor of non-guideline concordant chemotherapy is being 
covered through Medicaid insurance (OR 0.66, 95% CI: 0.50, 0.86) (46). Additionally, 
lacking insurance was found to be a predictor of nonguideline regimens among 
chemotherapy recipient (OR 0.47, 95% CI: 0.25, 0.92)(46).  
 A study examining guidelines for breast cancer treatment was conducted in 
Oklahoma among women who received breast conserving surgery (51). Women with a 
primary payer of Medicare/Medicaid (OR 0.45; 95% CI: 0.34, 0.62), Medicare (OR 0.59, 
95% CI: 0.45, 0.78), and those without insurance (OR 0.37, 95% CI: 0.21, 0.64) had 
 
13 
significantly lower odds than those without private insurance to have met guidelines for 
breast conserving surgery (51). 
 Patterns of postoperative radiation therapy use varied according to insurance in a 
study conducted using data from National Cancer Institute Surveillance, Epidemiology, 
and End Results (52). Radiation therapy after breast conserving surgery was more 
frequently omitted in women with Medicaid or uninsured status (p < 0.0001) (52). The 
odds of omitting radiation therapy following breast conserving surgery remained 
significantly associated with Medicaid (OR 1.14; 95% CI: 1.07, 1.21) and uninsured 
status (OR 1.29; 95% CI: 1.14, 1.47) in multivariable analysis (52). 
2.3.2 Distance to Facility and Rurality 
 Cancer patients who travel long distances to reach oncology care providers are at 
high risk of going untreated or being undertreated (53)(54). The influence of travel 
burden on cancer patients has been well documented in previous studies to suggest it 
negatively influences stage at diagnosis, appropriate treatment, prognosis, and quality of 
life (55). Breast cancer patients often require weekly and monthly healthcare services in 
order to closely and correctly follow the treatment regimen prescribed to them. 
Adherence to treatment guidelines may prove itself to be a difficult requirement in 
appropriateness of treatment among those who experience more travel distance to their 
treatment facility.  
 A study conducted in a rural region of the United States found a significant 
association between distance to treatment facility and guideline adherence (41). 
Compared to those residing within 5 miles of their treatment center, individuals living 5 – 
22 miles away (OR 0.47; 95% CI: 0.26, 0.83) and greater than 22 miles away (OR 0.45, 
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95% CI: 0.22, 0.92) were less likely to be guideline-concordant for adjuvant hormonal 
therapy (41). 
 Travel distance to treatment facilities may be significantly associated with 
completion of abnormal mammogram follow-up (11). In a study conducted among 
women in South Carolina, it was found that women who lived farther from their 
diagnosing mammography facility experienced a longer lapse of time taken to resolve 
their abnormal mammogram, irrespective of race (11). In the same study, women who 
lived the closest to their diagnosing mammography facility were more likely to have 
completed an abnormal mammogram follow-up (11).  
 In a study examining the receipt of radiotherapy as a metric to reflect quality of 
breast cancer care, it was found that increasing distance to the nearest radiotherapy 
provider was significantly associated with lower odds of receiving radiotherapy (OR 
0.54, 95% CI: 0.30, 0.97) for those living at least 20 miles from the nearest provider 
compared with those living less than 10 miles from the nearest provider (56). These 
findings may be indicative of the opportunities for public transportation among urban 
areas as opposed to the lack thereof in rural areas (56). The results of this study suggest 
that breast cancer patients living in areas greater than 10 miles from radiotherapy 
treatment facilities may need to be targeted for intervention to ensure they receive 
guideline-concordant care (56). 
2.3.3 Physician Availability 
In a study combining SEER data and the Health Resources and Services 
Administration Area Resource File to examine physician density and choice of breast 
conserving surgery versus mastectomy, the odds of having BCS versus mastectomy were 
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directly associated with radiation oncologist density (multiplicative change in odds for a 
single unit increase in radiation oncologist density [(ROD 1.02, 95% CI: 1.01–1.03); p < 
0.001], stating that the average odds of a patient having BCS instead of mastectomy 
increase by 2% for each increase in the number of radiation oncologists per 100,000 
people (57). Additionally, the multiplicative increase in odds for BCS for a single unit 
increase in radiation oncologist density was 1.06 (95% CI: 1.05, 1.07; p < 0.001), stating 
that for every increase in the number of radiation oncologists per 100,000 people, the 
average odds of a patient having BCS instead of mastectomy increased by 6% (57). 
A retrospective cohort study observed that women who lived a long distance  
from a radiation therapy center (greater than or equal to 50 miles) had extremely low 
rates of breast conserving surgery with radiation therapy (15.8%) (58). Woman of this 
≥50-mile cohort were most likely to undergo mastectomy (71.1%) (58). Women who 
lived 30-49 miles from radiation therapy had the next lowest rate of breast conserving 
surgery with radiotherapy (32.4%) and had a considerably high rate of mastectomy 
(64.1%)(58). In a similar study, distance to the closest radiation therapy facility was 
negatively associated with breast conserving surgery with radiation (per 5-mile increase: 
0.97 (95% CI: 0.95, 0.99); per 10-mile increase: (95% CI: 0.90, 0.98) per 15-mile 
increase 0.91 (95% CI: 0.86, 0.96) per 20-mile increase 0.88 (95% CI: 0.82, 0.95))(59); 
the odds ratio decreased 3% per 5-mile increase in distance.   
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Table 2.1 National Quality Forum (NQF) Treatment Quality Measures1 
Measure Measure Specifications 
Radiation Therapy 
Radiation therapy is administered within 
1 year (365 days) of diagnosis for 
women under age 70 receiving breast 
conserving surgery for breast cancer. 
Combination Therapy 
Combination chemotherapy is 
recommended or administered within 4 
months (120 days) of diagnosis for 
women under 70 with AJCC T1cN0M0 
or Stage IB - III hormone receptor 
negative breast cancer. 
Adjuvant Hormonal Therapy 
Tamoxifen or third generation aromatase 
inhibitor is recommended or 
administered within 1 year (365 days) of 
diagnosis for women with AJCC 
T1cN0M0 or Stage IB - III hormone 
receptor positive breast cancer. 
Radiation Therapy Following a 
Mastectomy 
Radiation therapy is recommended or 
administered following any mastectomy 
within 1 year (365 days) of diagnosis of 
breast cancer for women with ≥ 4 
positive regional lymph nodes. 
Needle Biopsy 
Image or palpation-guided needle biopsy 
to the primary site is performed to 
establish diagnosis of breast cancer. 
Breast Conservation Surgery Breast conservation surgery rate for 
women with AJCC clinical stage 0, I, or 
II breast cancer. 
1 Adapted from Cancer Programs Practice Profile Reports (CP3R) Rapid Quality 
Reporting System (RQRS). Released March, 2015. Accessed August 29, 2017. 
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CHAPTER 3 
METHODS 
 
3.1 STUDY DESIGN AND DATA SOURCE 
 We utilized an observational study design of breast cancer diagnosis and 
treatment data from 2004 to 2015 to analyze the association between i) geographic 
variation of needle biopsy receipt, and ii) patient- and/or health system predictors of 
guideline-concordant needle biopsy receipt among women with breast cancer diagnosed 
at CoC-accredited facilities. The data were obtained through the 2015 Participant Use 
File (PUF), which is derived from the NCDB. The NCDB is a collaborative program of 
the American College of Surgeons Commission on Cancer (CoC) and the American 
Cancer Society. Data represent a nationwide, hospital-based sample representing 70 
percent of incident U.S. breast cancer cases. The data contained in the PUF have been de-
identified in compliance with the Health Insurance Portability and Accountability Act 
(HIPAA) regulations. 
3.2 STUDY POPULATION 
 Patients who received a breast cancer diagnosis from January 1, 2004, to 
December 31, 2015, at a CoC-accredited facilities who were female, aged 40+ years at 
diagnosis, had non-Phyllodes tumors, had in situ and invasive tumors, were diagnosed at
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 a physician office or at the reporting facility and treated or made a decision not to treat at 
the reporting facility were identified and included in the cross-sectional analysis for both 
aims of the study (described in Table 3.1). Patients were excluded if the patient refused 
care and diagnosis, was medically unable to hold position for an image guided biopsy, 
required sub-areolar excision for nipple discharge, had a lesion that was too superficial, 
had breasts that were too small, had a lesion inaccessible by needle biopsy, if cancer was 
found in prophylactic mastectomy or through an elective procedure, had a benign high 
risk lesion that was diagnosed by needle biopsy which then required excisional biopsy, 
had discordant biopsy results compared to suspicious imaging, if the patient presented 
with co-morbid conditions that directly impacts delivery of the standard of care, and/or if 
they were diagnosed via cytology fine needle aspiration (FNA) only.  
3.3 MEASURES 
Outcome Variable 
  The outcome variable of interest was needle biopsy utilization, which is a NQF-
endorsed quality metric for breast cancer treatment. Needle biopsy was defined as having 
a core needle, fine needle aspiration, or incisional biopsy of the primary site performed 
for diagnosis. 
Covariates 
 The focus of Aim 1 was geographic variation in needle biopsy receipt, 
specifically distance to facility and urban/rural status. The independent variables of 
interest for Aim 2 included patient- and health system factors (see list of variables and 
definitions below).  
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 I. Geographic Variation  
Geographic variation in needle biopsy receipt was accessed by rurality, which was 
categorized into metropolitan, urban, and rural strata and sub-strata in the PUF (using the 
typography published by the USDA Economic Research Service) and great circle 
distance. Rurality was determined by matching the state and county Federal Information 
Processing Standard (FIPS) code of the patient recorded at the time of diagnosis against 
2013 urban-rural continuum codes published by the United States Department of 
Agriculture Economic Research Service (60). The matched codes form a classification 
scheme that distinguishes metropolitan counties by the population size of their 
metropolitan area, and nonmetropolitan counties by the degree of urbanization and 
adjacency to a metropolitan area. Rurality was categorized into three levels based on 
population (Table 4.1): metropolitan (counties in metro areas of more than 250,000 
people), urban (counties with an urban population of 2,500 – 20,000 people or counties 
with an urban population of greater than 20,000 people), and rural (counties with less 
than 2,500 people). These three levels were then each subsequently stratified into nine 
sub-strata based off adjacency to metropolitan area (defined in Table 4.1). Great circle 
distance, measured in miles, was the computed distance between the patient’s residence 
and the hospital that reported the case. Residential locations are based on the patient’s 
ZIP code centroid or on the city if the ZIP code was not available. Hospital locations 
were based on the street address for the facility. Great circle distance was treated as a 
continuous covariate in all analyses, but was further interpreted as a continuous variable 
with 10-mile increments. 
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 II. Patient Factors  
Age of the patient was reported at her last birthday before diagnosis. Age was 
categorized into five groups (40-49, 50-59 years, 60-69 years, 70-79 years, and 80 years 
or more). Race was divided into White, Black, Hispanic, and Asian/Pacific 
Islander/Other according to the race self-reported by the patient. Median household 
income for each patient’s area of residence was pre-coded by the NCDB through 
matching the ZIP code of the patient recorded at the time of diagnosis against files 
derived from the 2012 American Community Survey. Household income was categorized 
into quartiles based on equally proportioned income ranges among all US zip codes 
(<$38,000; $38,000 - $47,999; $48,000 - $62,999; $63,000 or more). Educational 
attainment was also pre-coded by the NCDB through matching the ZIP code of the 
patient recorded at the time of diagnosis against files derived from the 2012 American 
Community Survey. Educational attainment was a measure of the number of adults in the 
patient’s ZIP code who did not graduate high school, and is categorized into quartiles 
among all U.S. ZIP codes (21% or more, 13% - 20.9%, 7% - 12.9%, less than 7%). The 
patient’s primary insurance carrier at the time of initial diagnosis was pre-coded by the 
NDCB as Not Insured/Unknown, Private Insurance/Managed Care, Medicaid, Medicare, 
or Other Government. Comorbid conditions, as described by Charlson/Deyo in 1992, 
were analyzed from as many as ten reported ICD-9 or ICD-10 secondary diagnosis codes 
(61). The Charlson/Deyo Score is a weighted value derived from the sum of the scores 
from a selection of comorbid conditions (61). Individual Charlson/Deyo scores were not 
provided in the PUF. Instead, the Charlson/Deyo Score is derived from the highest score 
  
21 
that is calculated from using ICD-9 codes or the ICD-10 codes (Total Charlson/Deyo 
Score of 0; Total Charlson/Deyo Score of 1; Total Charlson/Deyo Score of 2; Total 
Charlson/Deyo Score of 3 or more). 
 In addition to the patient’s residence and demographics being included in this 
study, tumor characteristics were also examined as a predictor of receiving needle biopsy. 
We examined the i) clinically-determined size and/or extension of the primary tumor; ii) 
clinically determined absence or presence of regional lymph node metastasis and the 
extent to which the regional lymph node metastasis; iii) the applicable stage group based 
on the size/extension, regional lymph node metastasis, and absence or presence of distant 
metastasis; and iv) the behavior (in situ/invasive) of all cases. All of the tumor 
characteristics were clinically input by physicians into the NCDB and defined by the 
American Joint Committee on Cancer (AJCC) staging system. 
 III. Facility-level Factors 
Case volume was determined by calculating a weighted average of the number of 
breast cancer patients treated at each reporting cancer program and dividing programs 
into quintiles based on these averages. We calculated the case volume by facility for each 
year, then we took the 20th, 40th, 60th, and 80th percentiles to form five groups: Low 
(<71), Low/Medium (71-112), Medium (113-161), Medium/High (162-240), and High 
(>240). Facility type refers to an assigned classification given by the CoC program. Each 
facility reporting cases to the NCDB characterized facility type as a Community Cancer 
Program, Comprehensive Community Cancer Program, Academic/Research Program, 
Integrated Network Cancer Program, or Other. VA/Department of Defense facilities were 
not included in the PUF files, and therefore were not identifiable as a type of cancer 
  
22 
program (Figure 3.1)(62). Facility location was described by the US Census Division of 
the reporting facility (i.e., New England, Middle Atlantic, South Atlantic, East North 
Central, South Central, West North Central, West South Central, Mountain, and Pacific).  
Statistical Analysis 
All analyses were performed using SAS version 9.4 (Cary, North Carolina, USA). 
Geographic variation in needle biopsy receipt was described through great circle distance, 
region, and rurality. Patient-level factors and their association with guideline concordant 
care was described through age, race, income, education, insurance, comorbidity index, 
year of diagnosis, cancer behavior, clinical stage group, tumor size, and regional lymph 
node metastasis. The demographic characteristics were generated and reported as 
percentages for categorical variables and means and standard errors for continuous 
variables.  
Confounder selection began before the main analysis. A descriptive table was 
created using frequencies with a test of significance based on the Chi-Square test among 
categorical variables in relation to needle biopsy utilization. Tests of significance among 
continuous variables used the standard two-sample t-test. Bivariate analysis for needle 
biopsy utilization as the dependent variable and patient-/facility-level factors was initially 
performed. Any potential covariate with a p-value of <0.20 in a series of bivariate 
analyses were added to a full model. After the full model was produced, a backward 
confounder reduction process was conducted to remove covariates one at a time. If the 
beta coefficient was changed by 10% upon removing the coefficient, it was placed back 
into the model. Statistically significant covariates remained in the model. 
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 The main analysis, which examined the utilization of needle biopsy (1 = needle 
biopsy was utilized to diagnose breast cancer patient, 0 = needle biopsy was not utilized 
to diagnose breast cancer patient) across patient- and facility-level variables, was 
conducted through multivariable logistic regression modeling. In total, we ran three 
models: The first model was a model containing no fixed effects but only a random effect 
for facility nested within geographic area through an intercept; the second model 
contained individual-level covariates as fixed effects and the random effect term for 
facility nested within geographic area through an intercept; the final model contained 
individual- and facility-level covariates in addition to the random effect term for facility 
nested within geographic area through an intercept. Statistical significance was set at p ≤ 
0.05. Because our research question seeks to explore patient- and facility-level variation, 
the third model would be the most appropriate model to use in answering our research 
questions. The final model was a mixed effects model, with a random intercept for each 
facility nested within the facility location and fixed effects coefficients for the individual- 
and facility-level covariates. To capture how effective model 3 is at analyzing needle 
biopsy receipt, we used the area under the curve (AUC) of a Receiver Operating 
Characteristics curve (ROC). The ROC is a probability curve while the AUC represents 
the extent to which the model is capable of distinguishing between outcomes; in this case, 
our binary outcome of needle biopsy receipt.  
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Figure 3.1 CoC-Accredited Facility Type 
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Table 3.1 Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
40+ years Patient refusal 
Women Patient medically unable to hold 
position for image guided biopsy 
Primary cancer site is breast Patient requires sub-areolar 
excision for nipple discharge 
Women with non-Phyllodes tumors Lesion is too superficial 
Women with in situ and invasive tumors Breast is too small 
Women whose cases were diagnosed at staff 
physician office or at the reporting facility and 
treated or made decision not to treat at reporting 
facility 
Lesion inaccessible by needle 
biopsy 
Women who underwent biopsy (incisional, needle, 
aspiration) to primary site to establish diagnosis 
Cancer found in prophylactic 
mastectomy or through elective 
procedure 
 Benign high-risk lesions 
diagnosed by needle biopsy, 
requiring excisional biopsy 
 Discordant biopsy results 
compared to suspicious imaging 
 Patient presents with co-morbid 
conditions that directly impacts 
delivery to the standard of care 
 Diagnosed by cytology fine 
needle aspiration only 
 Women with metastatic disease 
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CHAPTER 4 
EXPLORING GEOGRAPHIC VARIATION AND PREDICTORS OF 
NEEDLE BIOPSY UTILIZATION IN COC-ACCREDITED FACILITIES1
                                                          
1  S. Barron, J. Eberth, A. Zgodic S. Adams, J. Hussey, D. Blackhurst, M. Hudson. To be 
submitted to Journal of Oncology Practice. 
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ABSTRACT 
INTRODUCTION: While improvements have been made in reducing breast cancer 
incidence and mortality over the past twenty years, disparities in breast cancer mortality 
remain. Understanding systematic differences in breast cancer treatment and quality of 
care remain at the epicenter of understanding breast cancer disparities. Needle biopsy is a 
less invasive and less expensive diagnostic test for breast cancer (as compared to 
excisional biopsy) and permits diagnosis while avoiding unnecessary surgery. This study 
was conducted to 1) examine how the National Quality Forum (NQF)-endorsed needle 
biopsy utilization measure varies geographically (i.e. state and region) and 2) determine 
the patient- and/or health system-level factors that predict guideline concordance among 
women with breast cancer who received treatment at Commission on Cancer-accredited 
facilities. METHODS: Patients who received a breast cancer diagnosis from January 1, 
2004 to December 31, 2015 were selected from the National Cancer Database, which 
captures information from over 70% of breast cancers in the United States. Patients 
whose breast cancer was diagnosed by needle biopsy were compared with patients who 
did not receive needle biopsy to diagnose their breast cancer by analyzing patient-, 
tumor-, and facility-level factors. Generalized linear mixed modeling was used to identify 
important predictors of needle biopsy receipt. RESULTS: Of 1,362,417 patients, 78.8% 
had received needle biopsy to diagnose their breast cancer. Patients were significantly 
more likely to undergo needle biopsy if they were nonwhite, had health insurance 
coverage through Medicaid or were uninsured/unknown form of insurance, had a 
comorbidity index score of 0, and were diagnosed with T3 lesions. Facility-level 
predictors of needle biopsy receipt were being diagnosed at a facility in the New England 
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census region and being diagnosed at a medium/high case volume facility. Patients who 
resided in metropolitan areas of 1 million people or more had increased odds of receiving 
a needle biopsy as compared to individuals from smaller urban and rural areas. 
CONCLUSION: This study suggests the significant impact that individual- and facility-
level predictors have in reducing health inequalities in breast cancer to support the 
optimization of facility access, and, thus, reduce breast cancer treatment disparities across 
patient populations. 
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INTRODUCTION 
 In the United States, an estimated 268,600 new cases of invasive breast cancer are 
expected to be diagnosed among women in 2019 along with 62,930 cases of non-invasive 
breast cancer (63). Irrespective of race and ethnicity, breast cancer is the most common 
cancer and the second leading cause of cancer death among women in the United States 
(1). While social, medical, and technological improvements have been made in reducing 
breast cancer incidence and mortality, disparities in breast cancer treatment and quality of 
care remain at the epicenter of understanding breast cancer mortality and improving the 
quality of life among breast cancer patients and survivors.  
To help improve breast cancer treatment quality and reduce breast cancer 
mortality, metrics such as the National Quality Forum (NQF) and Cancer Program 
Practice Profile Reports (CP3R), were created to benchmark performance, inform 
surveillance, and provide insight into quality improvement strategies. Past research has 
shown that care quality favorably impacts breast cancer survival (25). Additionally, 
recent literature suggests that geographic variation in breast cancer treatment exists, 
which may lead to disparities in the receipt of breast cancer treatment (19,20,34). If we 
learn why geographic variation exists in breast cancer treatment, improvements can be 
made in resource allocation and health policy implementation. More urban influence- and 
rurality- informed policies and resources would subsequently lead to improvements in the 
adherence to breast cancer treatment guidelines and, successively, improved breast cancer 
treatment and survival outcomes.  
The NCDB sources hospital registry data from more than 1,500 CoC-accredited 
facilities. Because these data represent 70% of newly diagnosed cancer cases in the U.S., 
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this sample of data is representative of the U.S. population that have obtained a cancer 
diagnosis (64). The CoC and NCDB developed the NCDB Quality Reporting Tools to 
evaluate the cancer care delivery among patients of CoC-accredited facilities. Treatment 
disparities are prevalent across several NCDB quality indicators, such as needle biopsy 
utilization (19,20,65). Needle biopsy proves itself to be a more suitable aspect of breast 
cancer diagnosis, care, and treatment because it is a less invasive form of breast cancer 
diagnosis (as compared to excisional biopsy), less costly, and permits diagnosis while 
avoiding unnecessary surgery.  
A cross-sectional study of needle biopsy receipt in CoC-accredited facilities 
conducted between 2003 and 2008 provided justification for this study (20). Using the 
same data source as the present study, Williams et al. examined predictors of needle 
biopsy utilization while also exploring how needle biopsy utilization increased over time. 
While their study provided insight into the relationship between key patient and facility-
level factors and needle biopsy utilization, an updated assessment is needed to determine 
whether uptake and geographic disparities in needle biopsy receipt have improved. This 
study was conducted to 1) examine how the NQF-endorsed needle biopsy utilization 
measure varies geographically (region) and 2) determine the patient- and/or health 
system-level factors that predict guideline concordance among women with breast cancer 
who received treatment at CoC-accredited facilities. This study hypothesized that needle 
biopsy utilization will be less likely among individuals who have a greater circle distance 
to facility, are rural, less educated, older, are ethnic/racial minorities, not privately 
insured, and have a lower median household incomes. 
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METHODS 
Data 
 The data were obtained through the 2015 Participant Use File (PUF) derived from 
the NCDB. Patients who received a breast cancer diagnosis from January 1, 2004 to 
December 31, 2015 at CoC-accredited facilities were identified and included in the cross-
sectional analysis for both aims of the study. In addition to being female, patients were 
also required to be an adult with an age of 40 years and above, have non-Phyllodes 
tumors, had in situ and invasive tumors, were diagnosed at a physician office or at the 
reporting facility and treated or made a decision not to treat at the reporting facility 
(Table 3.1).  
Geographic Variation 
 Geographic variation was examined through i) urban-rural status, ii) great circle 
distance, and iii) facility location. Rurality was estimated in the PUF by matching the 
state and five-digit county Federal Information Processing Standard (FIPS) code of the 
patient recorded at the time of diagnosis against 2013 urban-rural continuum codes 
derived from the U.S. Department of Agriculture and Economic Research Service (57). 
The FIPS-matched codes form a classification scheme that distinguishes metropolitan 
counties by the population size of their metropolitan area, and nonmetropolitan counties 
by the degree of urbanization and adjacency to a metropolitan area. From this 
classification, areas are then subdivided into three metropolitan and six nonmetropolitan 
groupings, which are determined by population size of the county and adjacency to 
metropolitan areas. Great circle distance, measured in miles, is based on the distance 
between residential locations (using the patient’s ZIP code centroid) and hospital 
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locations (using the street address of the facility). In this analysis, great circle distance 
was analyzed as a continuous variable, but was further interpreted as a continuous 
variable with 10-mile increments.  
Patient Factors 
 Age of the patient is reported at her last birthday before diagnosis. Age was 
categorized into five groups: 40-49, 50-59, 60-69, 70-79, and 80+. Race was divided into 
White, Black, Hispanic, Asian/Pacific Islander and Other, according to the race self-
reported by the patient. Median household income for each patient’s area of residence 
was pre-coded by the NCDB through matching the ZIP code of the patient recorded at the 
time of diagnosis against files derived from the 2012 American Community Survey data. 
Household income was categorized into quartiles based on equally proportioned income 
ranges among all US ZIP codes (<$38,000; $38,000 - $47,999; $48,000 - $62,999; 
$63,000 or more). Educational attainment was pre-coded by the NCDB through matching 
the ZIP code of the patient recorded at the time of diagnosis against files derived from the 
2012 American Community Survey data. Educational attainment is a measure of the 
number of adults in the patient’s zip code who did not graduate high school, and was 
categorized into quartiles among all US ZIP codes (21% or more, 13% - 20.9%, 7% - 
12.9%, Less Than 7%). Comorbid conditions, as described by Charlson/Deyo in 1992 
were analyzed from as many as ten reported ICD-9 or ICD-10 secondary diagnosis codes 
(61). The Charlson/Deyo Score is a weighted value derived from the sum of the scores 
from a selection of comorbid conditions (61). Individual Charlson/Deyo scores are not 
provided in the PUF. Instead, the Charlson/Deyo Score was derived from the highest 
score that is calculated from using ICD-9 codes or the ICD-10 codes (Total 
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Charlson/Deyo Score of 0; Total Charlson/Deyo Score of 1; Total Charlson/Deyo Score 
of 2; Total Charlson/Deyo Score of 3 or more). The patient’s primary insurance carrier at 
the time of initial diagnosis was examined as a system-level exposure. Insurance status 
was pre-coded by the NCDB as Not Insured, Private Insurance/Managed Care, Medicaid, 
Medicare, or Other Government.  
In addition to the patient’s residence and demographics being included in this 
study, tumor characteristics will also be examined by status of needle biopsy receipt and 
as a predictor of receiving needle biopsy. We examined the i) clinically-determined size 
and/or extension of the primary tumor; ii) clinically determined absence or presence of 
regional lymph node metastasis and the extent to which the regional lymph node 
metastasis; iii) the applicable stage group based on the size/extension, regional lymph 
node metastasis, and absence or presence of distant metastasis; and iii) the behavior (in 
situ/invasive) of all cases. All of the tumor characteristics were clinically input by 
physicians into the NCDB and defined by the American Joint Committee on Cancer 
(AJCC) staging system. 
Facility-Level Factors 
 Case volume was determined by calculating a weighted average of the number of 
breast cancer patients treated at each reporting cancer program and dividing programs 
into quintiles based on these averages. We calculated the case volume by facility for each 
year, then we took the 20th, 40th, 60th, and 80th percentiles to form five groups: Low 
(<71), Low/Medium (71-112), Medium (113-161), Medium/High (162-240), and High 
(>240). Facility type refers to an assigned classification given by the CoC Accreditation 
Program. Each facility reporting cases to the NCDB characterized facility type as a 
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Community Cancer Program, Comprehensive Community Cancer Program, 
Academic/Research Program, Integrated Network Cancer Program, or Other. 
VA/Department of Defense facilities are not included in the PUF files, and therefore were 
not identifiable as a type of cancer program (Figure 3.1)(62). Facility location was 
derived from the U.S. Census Division of the reporting facility. All fifty states were 
categorized into 9 regions based on geographical location. 
Data Analysis 
All analyses were performed using SAS version 9.4 (Cary, North Carolina, USA). 
Geographic variation in needle biopsy receipt was described through great circle distance, 
region, and rurality. Patient-level factors and their association with guideline concordant 
care was described through age, race, income, education, insurance, comorbidity index, 
year of diagnosis, cancer behavior, clinical stage group, tumor size, and regional lymph 
node metastasis. The demographic characteristics were generated and reported as 
percentages for categorical variables and means and standard errors for continuous 
variables.  
Confounder selection began before the main analysis. A descriptive table was 
created using frequencies with a test of significance based on the Chi-Square test among 
categorical variables in relation to needle biopsy utilization. Tests of significance among 
continuous variables used the standard two-sample t-test. Bivariate analysis for needle 
biopsy utilization as the dependent variable and patient-/facility-level factors was initially 
performed. Any potential covariate with a p-value of <0.20 in a series of bivariate 
analyses were added to a full model. After the full model was produced, a backward 
confounder reduction process was conducted to remove covariates one at a time. If the 
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beta coefficient was changed by 10% upon removing the coefficient, it was placed back 
into the model. Statistically significant covariates remained in the model. 
 The main analysis, which examined the utilization of needle biopsy (1 = needle 
biopsy was utilized to diagnose breast cancer patient, 0 = needle biopsy was not utilized 
to diagnose breast cancer patient) across patient- and facility-level variables, was 
conducted through multivariable logistic regression modeling. In total, we ran three 
models: The first model was a model containing no fixed effects but only a random effect 
for facility nested within geographic area through an intercept; the second model 
contained individual-level covariates as fixed effects and the random effect term for 
facility nested within geographic area through an intercept; the final model contained 
individual- and facility-level covariates in addition to the random effect term for facility 
nested within geographic area through an intercept. Statistical significance was set at p ≤ 
0.05. Because our research question seeks to explore patient- and facility-level variation, 
the third model would be the most appropriate model to use in answering our research 
questions. The final model was a mixed effects model, with a random intercept for each 
facility nested within the facility location and fixed effects coefficients for the individual- 
and facility-level covariates. To capture how effective model 3 is at analyzing needle 
biopsy receipt, we used the AUC of a ROC. 
RESULTS 
Demographics of Overall Study Population 
After exclusion criteria were applied, the study population included 1,362,417 
women for the years used in this analysis of NCDB data (2004-2015). Sample 
characteristics of the patients in this study are displayed in Table 4.1. The number of 
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patients per year ranged from a low of 99,057 in 2004 to a high of 125,442 in 2015 
(Table 4.1). Most patients were white (80.2%), earned an income of $63,000+ per year 
(37.1%), and were insured with private insurance or had managed care (50.9%). Most 
patients presented with stage I disease (35.4%), were from the South Atlantic (21.9%) 
and were treated at comprehensive community cancer programs (50.4%). The mean 
travel distance for patients was 16.0 miles, with most patients residing in metropolitan 
counties comprised of populations ≥1,000,000 (54.1%).  
Needle Biopsy vs. Other Biopsy 
Needle biopsy was performed for diagnosis in 78.8% of women. All patient, 
facility, and tumor factors examined were significantly different (p < 0.0001)  in their 
distribution when stratified and compared by needle biopsy receipt (Table 4.2). The 
percentage of women receiving needle biopsy increases with comorbidity index, facility 
case volume, and year of diagnosis. Conversely, the trend of women receiving other 
forms of biopsy for breast cancer diagnosis decreased across all years in the study period. 
Of the women who were diagnosed with in situ forms of breast cancer, 66% were 
diagnosed using needle biopsy compared to 34% who were not diagnosed with needle 
biopsy. 82.8% of women with invasive forms of breast cancer were diagnosed with 
needle biopsy, compared to 17.2% of women that were diagnosed with other forms of 
biopsy.  
Predictors of Needle Biopsy, 2004 – 2015 
 Median income and educational attainment of the population were dropped from 
the analyses in Model 2 (p = 0.3934 and 0.7831, respectively) and Model 3 (p = 0.3220 
and 0.7116, respectively) because these covariates were not significant. While Model 2 
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represents individual-level factors that predict needle biopsy receipt, Model 3 was chosen 
as the final model as it displays all of the covariates, at the individual and facility level, 
that predict needle biopsy receipt. The AUC ROC at 0.7838, which was deemed 
satisfactory moving forward with the analysis. Because model 3 answers our research 
questions around needle biopsy receipt in relation to individual- and facility-level 
predictors, the AUC ROC obtained demonstrates that model 3 is capable of 
distinguishing between our binary outcome. The results of the logistic regression models 
run are displayed in Table 4.3. Factors that predicted receipt of needle biopsy were 
assessed over the entire study period (2004 – 2015). 
I. Geographic Variation in Needle Biopsy Receipt 
Odds ratios (ORs) for each stratum of rurality were less than 1.0, with our comparison 
group (Metropolitan Areas of 1,000,000+ people) having the highest odds of receiving 
needle biopsy treatment. For example, the odds of needle biopsy receipt among 
metropolitan areas of 250,000-1 million were 0.956 (OR 0.956, 95% CI: 0.930, 0.983) 
times the odds of needle biopsy receipt for individuals who live in metropolitan areas of 
greater than 1 million people. Therefore, patients who live in metropolitan areas of 
150,000-1 million people have odds of needle biopsy receipt 4.4% lower than patients 
who live in metropolitan areas of greater than 1 million people. This trend is seen for 
other strata of rurality as well. Patients who are from urban areas of more than 20,000 and 
adjacent and nonadjacent to metropolitan areas people were, respectively, 13.9% (OR 
0.861, 95% CI: 0.831, 0.892) and 13.4% (OR 0.866, 95% CI: 0.814, 0.922) less likely to 
receive needle biopsy than patients who were form metropolitan areas of greater than 1 
million people. Patients from smaller urban areas of 2,500-19,999 that were adjacent and 
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nonadjacent to metropolitan areas were, respectively, 10.1% (OR 0.899, 95% CI: 0.869, 
0.929) and 12.5% (OR 0.875, 95% CI: 0.834, 0.918) less likely to receive needle biopsy 
as compared to patients who were from metropolitan areas of more than 1 million people. 
Patients who are from rural areas with less than 2,500 people and not adjacent to a 
metropolitan area are 10.9% less likely to receive needle biopsy as compared to patients 
that are from metropolitan areas of more than 1 million people (OR 0.891, 95% CI: 
0.834, 0.952). Similarly, patients who are from rural areas with less than 2,500 people 
and are adjacent to a metropolitan area are 11.5% less likely to receive needle biopsy as 
compared to patients that are from metropolitan areas of more than 1 million people (OR 
0.885, 95% CI: 0.832, 0.942). The odds ratio estimates for great circle distance was 
computed by comparing the average distance for patients who received needle biopsy 
against patients who did not receive needle biopsy. In this sample, great circle distance 
yielded odds ratio estimates that were significant, but weak in magnitude. For a 10-mile 
increase in great circle distance, the odds of needle biopsy receipt decrease by a factor of 
0.0043 (OR: 0.99957, 95% CI: 0.99956, 0.99958) compared to patients who do not 
receive needle biopsy.  
II. Individual-Level Factors Predicting Needle Biopsy Receipt 
Patients aged 50-59 years had odds of receiving needle biopsy 11.5% greater than 
patients aged 40-49 years (OR: 1.115, 95% CI: 1.099, 1.130). Patients who were 60-69 
years of age at the time of diagnosis had the highest odds of needle biopsy receipt (OR 
1.200, 95% CI: 1.182, 1.219) while patients who were 80 years of age or older had the 
lowest odds of needle biopsy receipt (OR: 0.975, 95% CI: 0.955, 0.996). Race was 
associated with needle biopsy receipt, but all OR estimates were weak in magnitude and 
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close to the null value of 1.0. Patients who were on Medicaid at the time of breast cancer 
diagnosis were 1.056 times as likely to receive needle biopsy than patients who had 
private insurance/managed care (OR 1.056, 95% CI: 1.031, 1.081). Interestingly, patients 
who had Medicare at the time of breast cancer diagnosis were 0.979 times as likely to 
receive needle biopsy than patients who had private insurance/managed care (OR 0.979, 
95% CI: 0.965, 0.993). Because most patients in these data do not experience 
comorbidity, all OR estimates were less than 1.0; patients with a comorbidity index of 1 
were 8.5% less likely to receive needle biopsy compared to individuals with a 
comorbidity index of 0 (OR 0.915, 95% CI: 0.902, 0.927). Individuals with a comorbidity 
index of 3+ were 14.9% less likely to receive needle biopsy compared to individuals with 
a comorbidity index of 0 (OR 0.851, 95% CI: 0.802, 0.902). Compared with patients 
diagnosed in 2004, those diagnosed in 2015 were 4.626 times as likely to receive needle 
biopsy (OR: 4.626, 95% CI: 4.513, 4.743). This increasing trend in odds ratio is prevalent 
for all years examined in this model. The strongest association in tumor size/extension is 
seen for patients with T3 tumors. Patients with T3 tumors were 10.671 times as likely to 
receive needle biopsy as compared to patients with T0 tumors of the breast (OR 10.671, 
95% CI: 9.947, 1.450). Patients who had clinically-determined presence of regional 
lymph node metastasis classified as “Unknown” by the AJCC were 1.642 times as likely 
to undergo needle biopsy as compared to patients who have no presence of regional 
lymph node metastasis (OR 1.642, 95% CI: 1.610, 1.675). Patients diagnosed with stage I 
breast cancer have odds of receiving needle biopsy 45.6% lower than patients diagnosed 
with stage 0 breast cancer (OR 0.544, 95% CI: 0.521, 0.567). Patients diagnosed with an 
unknown stage of breast cancer had odds of receiving needle biopsy 66.1% lower than 
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patients diagnosed with stage 0 breast cancer (OR 0.339, 95% CI: 0.328, 0.351). Patients 
diagnosed with invasive forms of breast cancer were more likely to obtain needle biopsy 
as compared to patients with in-situ forms of breast cancer (OR 3.110, 95% CI: 3.057, 
3.163). 
III. Facility-Level Factors Predicting Needle Biopsy Receipt 
Facility type was not significant when included in the full model; however, because 
facility type explores breast cancer care variation through facility-level factors, it was left 
in the analysis. Patients who had their breast cancer diagnosed at high case-volume 
facilities were 1.506 times as likely to undergo needle biopsy than patients who were 
diagnosed at low case-volume facilities (OR 1.506, 95% CI: 1.446, 1.568). Therefore, 
patients diagnosed at high case-volume facilities have odds of receiving needle biopsy 
50.6% greater than patients diagnosed at low case-volume facilities. Patients who had 
their breast cancer diagnosed at medium/high case-volume facilities had the highest odds 
of receiving needle biopsy; patients diagnosed at medium/high case volume facilities 
have odds of receiving needle biopsy 53.8% greater than patients diagnosed at low case-
volume facilities (OR 1.538, 95% CI: 1.489, 1.589). Patients who were diagnosed in the 
New England census region had a higher likelihood of having needle biopsy as compared 
to those diagnosed in other census regions. Patients who were diagnosed in the Middle 
Atlantic census region had odds of undergoing needle biopsy 32.2% lower than patients 
diagnosed in the New England census region (OR 0.678, 95% CI: 0.548, 0.840). 
Similarly, patients who were diagnosed in the East South Central census region had odds 
of receiving needle biopsy 7.4% lower than patients diagnosed in the New England 
census region (OR 0.926, 95% CI: 0.723, 1.186). 
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IV. Random Effect for Facility-Driven Variability in Needle Biopsy Receipt 
In our analyses, for all three models, we used a random intercept for each facility 
nested within its geographic area. Therefore, each patient had an additional effect coming 
from the facility they are associated with when the models are conducted and analyzed. 
The variance and standard error of each of the random intercepts are reported in Table 
4.4. In model 1, the model containing only the random effect of facility within region, the 
variance estimate is 0.6795 (95% CI: 0.628, 0.738). We conducted a Likelihood Ratio 
Test to examine whether the covariance estimate was different from 0. We obtained a p-
value of <0.0001, indicating that there is significant variation between facilities when 
controlling for region and that this random intercept is needed in the model. Because the 
analysis in model 1 yielded a significant estimate, model 2 and model 3 were also 
conducted with the random effect estimate. 
 Model 2 displays the individual-level variables and the random effect, therefore 
we controlled for the variation that comes from the individual-level variables through 
fixed effects. After this individual-level variation is accounted for, the remaining 
variation is captured by the random effect, which was 0.7642 (95% CI: 0.706, 0.830). 
This significant estimate was higher than that of model 1, which was unexpected as the 
random effect estimate should have decreased because these individual-level covariates 
should have reduced the amount of free-floating variation in the data and, hence, should 
have captured more of the variation in needle biopsy receipt. More exploration as to why 
this result was obtained is needed. 
 Model 3 captures the individual-level variation with the facility-level covariates. 
The random effect estimate is 0.6785 (95% CI: 0.627, 0.736), therefore there is still 
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variation between facilities. However, although the random effect estimate decreased 
once facility-level variables were included in addition to individual-level variables, these 
covariates do not account for all of the possible variation between the facilities.  
DISCUSSION 
 The present study demonstrated significant geographic, facility-level, and 
individual-level predictors of needle biopsy receipt. Needle biopsy use varied 
geographically, with patients from large metropolitan areas experiencing the highest odds 
of undergoing needle biopsy. Facility-level factors that were associated with needle 
biopsy receipt were hospital census region and facility case volume. Hospitals in the New 
England census region and high case-volume facilities were the strongest predictors of 
needle biopsy receipt at the facility-level. Individual-level factors that were associated 
with needle biopsy receipt were race, age, insurance status, and comorbidity index score. 
Tumor characteristics, such as tumor size/extension, lymph node metastasis, clinical 
stage group, and behavior, were also associated with needle biopsy receipt.  
 Individual-level factors in the present study most strongly associated with needle 
biopsy receipt were characteristics of the tumor, insurance status, and age, similar to 
Williams et al. (23). Our study also found that race yielded OR estimates that were 
attenuated towards the null value of 1.0. One possible interpretation of the associations 
that were considerably weak in magnitude is our lack of an interaction term in the 
regression analyses. Including an interaction term in our regression analyses would have 
allowed the relationship between needle biopsy receipt and an independent variable to 
differ across categorized levels of a second independent variable. Specifically, an 
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interaction term between comorbidity index and age would better explore a patient’s risk 
and build a more accurate patient profile in predicting needle biopsy receipt. 
The effect of socioeconomic status on quality of breast cancer care is explored 
throughout the scientific literature (40,41,44–47,49,50). In our analyses, area income and 
percentage of the population without a high school degree were not significant and were, 
thus, excluded from our study. Excluding these variables from our analysis put a greater 
emphasis on exploring individual-level predictors of needle biopsy receipt. Williams et 
al., however, found significant associations in income and percentage of population 
without a high school degree in their overall analysis, which they deemed were 
significant socioeconomic predictors of needle biopsy receipt (23). Once Williams et al. 
restricted the analysis to only the year 2008, however, the only sociodemographic 
predictors that were persistently associated with receipt of needle biopsy were race and 
percentage of population without a high school degree (23). This particular finding of 
Williams et al. and our study may be a result of i) a decrease in disparities over time 
among women diagnosed with breast cancer and/or ii) the increasing use of needle biopsy 
as compared to other forms of biopsy to diagnose breast cancer. 
Facility case-volume is known to have an impact on breast cancer treatment 
quality (60). For example, Eberth et al. found that low case volume facilities were more 
likely to omit needle biopsy as compared to high case volume facilities (60). Our study 
added to this body of evidence by finding that patients who had received a breast cancer 
diagnosis at a high case volume facility were at increased odds of receiving needle 
biopsy. Furthermore, facility case volume was the strongest predictor of needle biopsy at 
the facility-level. Williams et al. suggest that facility case volume is more important than 
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facility type as a predictor for receiving needle biopsy (23). Our analysis confirmed this 
finding as well. Although facility type was insignificant in the regression analyses, it was 
left in the model to gain more insight into facility-level factors that predict needle biopsy 
receipt.  
Tumor size/extension was the most significant individual-level predictor of needle 
biopsy receipt in our study. Individuals who had been diagnosed with T3 tumors had the 
highest odds of receiving needle biopsy as compared to the other sizes/extensions 
examined in this study. Williams et al. found that tumor stage was an important 
individual-level predictor. While tumor stage was a significant predictor of needle biopsy 
in our study, tumor size/extension had nearly 10-fold increases in odds as compared to 
tumor stage. 
 This study was limited through its use of pre-coded and pre-populated registry 
data obtained through the NCDB PUF. In particular, the coding for the diagnostic 
procedure does not distinguish core, FNA, and incisional biopsies. Incisional biopsy 
patients could not be reliably separated from the needle biopsy cohort. Therefore, the 
needle biopsy cohort includes this group of patients. Equivalently, we could not 
differentiate patients undergoing FNA from those that had core needle biopsy. This 
comparison would have added to the scientific body of literature by portraying a more in-
depth view of needle biopsy methods and how they differ across patient populations. 
There are predictors of needle biopsy receipt that were not captured explicitly in our 
dataset, including the expertise of the physician and the specialty of the treating surgeon.  
 This present study demonstrates the individual- and facility-level predictors of 
needle biopsy while also exploring geographical variation in receipt of needle biopsy. 
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The large sample size of over a million patients from multiple institutions and facilities 
increases the robustness of the overall model and builds a theoretically sound framework 
into the patient profiles of individuals who receive needle biopsy as a diagnostic tool in 
their breast cancer. Our study also explores four different tumor characteristics and how 
they influence a patient’s odds of needle biopsy receipt, which is an area of individual-
level predictors that Williams et al. fail to examine. 
 In conclusion, we explored geographical variation in guideline concordant breast 
cancer care through rurality and urban influence as well as individual- and facility-level 
predictors of guideline concordant care in a nationally representative sample of over one 
million women. This study suggests the significant impact that individual- and facility-
level predictors have in reducing health inequalities in breast cancer care to support the 
optimization of facility access, and, thus, reduce breast cancer treatment disparities across 
patient populations. Furthermore, this study adds to literature to build a more accurate 
and representative patient profile among individuals who receive breast cancer care that 
is in accordance to current practice guidelines. Having access to guideline-concordant 
breast cancer care is important in reducing the overall breast cancer burden. Breast cancer 
interventions should target low case-volume facilities in order to maximize the utilization 
of needle biopsy and, thus, conduct guideline concordant breast cancer care.  
  
46 
Table 4.1 Patient demographic and clinical characteristics of breast cancer patients from 
the NCDB, 2004 – 2015 (N = 1,362,417) 
Characteristic 
No. of 
Patients % 
Entire cohort 1,362,417 100% 
Patient Factors 
  
  
Age, years   
  40-49 234,282 17.2 
  50-59 346,569 25.4 
  60-69 365,267 26.8 
  70-79 265,452 19.5 
  80+ 150,847 11.1 
Race/Ethnicity   
  White 1,092,506 80.2 
  Black 150,077 11.0 
  Hispanic 60,832 4.5 
  Asian/Pacific Islander 40,168 3.0 
  Other 18,834 1.4 
Income   
  <$38,000 202,206 14.9 
  $38,000-$47,999 285,980 21.0 
  $48,000-$62,999 367,413 27.0 
  $63,000+ 505,378 37.1 
Population Without HS Degree   
  21%+ 190,388 14.0 
  13%-20.9% 319,754 23.5 
  7% - 12.9% 457,657 33.6 
  <7% 393,710 28.9 
Insurance Status   
  Not Insured 25,324 1.9 
  Private Insurance/Managed Care 692,935 50.9 
  Medicaid 67,675 5.0 
  Medicare 546,812 40.1 
  Other Government 10,776 0.8 
  Insurance Status Unknown 19,195 1.4 
Urban/Rural Residence   
Metro Counties:   
   1 million+ 400,115 55.3 
  250,000-1 million 161,948 22.4 
  <250,000 73,549 10.2 
Urban Counties:   
  20,000+, adjacent to metro area 27,713 3.8 
  20,000+, not adjacent to metro area 10,210 1.4 
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  2,500-19,999, adjacent to metro area 28,231 3.9 
  2,500-19,999, not adjacent to metro area 11,807 1.6 
Rural Counties:   
  <2,500, adjacent to metro area 5,232 0.70 
  <2,500, not adjacent to metro area 4,690 0.70 
Comorbidity Index   
  0 1,134,788 83.3 
  1 184,056 13.5 
  2 34,218 2.5 
  3+ 9,355 0.7 
Year of Diagnosis   
  2004 99,057 7.3 
  2005 100,751 7.4 
  2006 103,764 7.6 
  2007 107,824 7.9 
  2008 111,360 8.2 
  2009 116,166 8.5 
  2010 113,683 8.3 
  2011 117,332 8.6 
  2012 118,963 8.7 
  2013 122,890 9.0 
  2014 125,185 9.2 
  2015 125,442 9.2 
Tumor Characteristics***   
Tumor Size/Extension   
  T0 7,918 0.6 
  Ti 271,339 19.9 
  T1 512,079 37.6 
  T2 197,561 14.5 
  T3 34,621 2.5 
  T4 24,270 1.8 
  Unknown 314,179 23.1 
Lymph Node Metastasis   
  N0 933,237 68.5 
  N1 14,956 1.1 
  N2 17,705 1.3 
  N3 8,133 0.6 
  Unknown 388,386 28.5 
Clinical Stage Group   
  0 265,768 19.5 
  I 482,004 35.4 
  II 227,886 16.7 
  III 57,846 4.2 
  Unknown 327,639 24.0 
Behavior   
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  In situ 322,011 23.6 
  Invasive 1,040,406 76.4 
 Mean SD 
Great Circle Distance, miles 16.0 64.8 
   
Facility Factors 
Hospital Census Region   
  New England 88,478 6.5 
  Middle Atlantic 211,484 15.5 
  South Atlantic 298,714 21.9 
  East North Central 264,852 19.4 
  East South Central 82,491 6.1 
  West North Central 107,171 7.9 
  West South Central 93,837 6.9 
  Mountain 84,299 4.0 
  Pacific 161,091 11.8 
Facility Type     
  Community Cancer Program 151,299 11.1 
  Comprehensive Community Cancer 
Program 
686,815 50.4 
  Academic/Research Program 367,586 27.0 
  Integrated Network Cancer Program 156,717 11.5 
Facility Volume   
  Low (<71) 271,119 19.9 
  Low/Medium (71-112) 271,223 19.9 
  Medium (113-161) 272,413 20.0 
  Medium/High (162-240) 273,954 20.1 
  High (>240) 273,708 20.1 
Comorbidity index is based on Charlson-Deyo score. Column percentages may not equal 
100% due to rounding. Abbreviations: SE = Standard Error, HS = High School. 
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Table 4.2 Characteristics of breast cancer patients by needle biopsy receipt from the 
NCDB, 2004-2015 (N = 1,362,417) 
 Needle Biopsy 
Receipt  
(n = 1,074,147) 
No Needle 
Biopsy Receipt 
 (n = 288,270) 
 
Patient Factors n % a, b n % a, b P-
value* 
Age, years     <.0001 
  40-49 178,846 76.3 55,436 23.7  
  50-59 272,565 78.6 74,004 21.4  
  60-69 294,476 80.6 70,791 19.4  
  70-79 211,624 80.0 53,828 20.0  
  80+ 116,636 77.3 34,211 22.7  
Race/Ethnicity     <.0001 
  White 859,901 78.7 232,605 21.3  
  Black 118,700 79.1 31,377 20.9  
  Hispanic 48,862 80.3 11,970 19.7  
  Asian/Pacific Islander 32,102 79.9 8,066 20.1  
  Other 14,582 77.4 4,252 22.6  
Income     <.0001 
  <$38,000 158,526 78.4 43,680 21.6  
  $38,000-$47,999 226,363 79.2 59,617 20.8  
  $48,000-$62,999 291,685 79.4 75,728 20.6  
  $63,000+ 396,481 78.5 108,897 21.5  
Population Without HS Degree     <.0001 
  21%+ 150,133 78.9 40,255 21.1  
  13% - 20.9% 250,974 78.5 68,780 21.5  
  7% - 12.9% 360,682 78.8 96,975 21.2  
  <7% 311,680 79.2 82,030 20.8  
Insurance Status     <.0001 
  Not Insured 20,515 81.0 4,809 19.0  
  Private Insurance/Managed Care 542,068 78.2 150,867 21.8  
  Medicaid 55,131 81.8 12,244 18.2  
  Medicare 433,195 79.2 113,617 20.8  
  Other Government 8,670 80.5 2,106 19.5  
  Insurance Status Unknown 14,568 75.9 4,627 24.1  
Urban/Rural Residence     <.0001  
Metro Counties:      
  1 million+ 345,508 86.4 54,607 13.6  
  250,000-1 million 140,689 86.9 21,259 13.1  
  < 250,000 64,426 87.6 9,123 12.4  
Urban Counties:        
  20,000+, adjacent to metro area 23,867 86.1 3,846 13.9  
  20,000+, not adjacent to metro area 8,849 86.7 1,361 13.3  
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  2,500-19,999, adjacent to metro area 24,602 87.1 3,629 12.9  
  2,500-19,999, not adjacent to metro 
area 
10,171 
86.1 
1,636 
13.9 
 
Rural Counties:        
  <2,500, adjacent to metro area 4,528 86.5 704 13.5  
  <2,500, not adjacent to metro area 4,092 87.2 598 12.8  
Comorbidity Index**     <.0001 
  0 893,005 78.7 241,783 21.3  
  1 146,105 79.4 37,951 20.6  
  2 27,397 80.1 6,821 19.9  
  3+ 7,640 81.7 1,715 18.3  
Year of Diagnosis     <.0001 
  2004 61,381 62.0 37,676 38.0  
  2005 65,875 65.4 34,876 34.6  
  2006 70,789 68.2 32,975 31.8  
  2007 76,311 70.8 31,513 29.2  
  2008 82,191 73.8 29,169 26.2  
  2009 90,868 78.2 25,298 21.8  
  2010 93,448 82.2 20,235 17.8  
  2011 100,083 85.3 17,249 14.7  
  2012 103,445 87.0 15,518 13.0  
  2013 107,752 87.7 15,138 12.3  
  2014 110,915 88.6 14,270 11.4  
  2015 111,089 88.6 14,353 11.4  
Tumor Characteristics***      
Tumor Size/Extension <.0001 
  T0 3,129 39.5 4,789 60.5  
  Ti 198,750 73.2 72,589 26.8  
  T1 440,828 86.1 71,251 13.9  
  T2 174,440 88.3 23,121 11.7  
  T3 31,102 89.8 3,519 10.2  
  T4 21,258 86.0 3,462 14.0  
  Unknown  204,640 65.1 109,539 34.9  
Lymph Node Metastasis <.0001 
  N0 759,044 81.3 174,193 18.7  
  N1 10,846 72.5 4,110 27.5  
  N2 15,042 85.0 2,663 15.0  
  N3 6,959 85.6 1,174 14.4  
  Unknown 282,256 72.7 106,130 27.3  
Clinical Stage Group <.0001 
  0 193,757 72.9 72,011 27.1  
  I 414,639 86.0 67,365 14.0  
  II 200,595 88.0 27,291 12.0  
  III 50,442 87.2 7,404 12.8  
  Unknown 213,894 65.3 113,745 34.7  
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Behavior     <.0001 
  In situ 212,579 66.0 109,432 34.0  
  Invasive 861,568 82.8 178,838 17.2  
      
Great Circle Distance Mean SE Mean SE <.0001† 
  Miles 15.6 0.06 17.0 0.14  
 Needle Biopsy 
Receipt 
(n = 1074147) 
No Needle 
Biopsy Receipt 
(n = 288270) 
 
Facility Factors n % n % P-value 
Hospital Census Region     <.0001 
  New England 69,128 78.1 19,350 21.9  
  Middle Atlantic 155,173 73.4 56,311 26.6  
  South Atlantic 235,420 78.8 63,294 21.2  
  East North Central 212,504 80.2 52,348 19.8  
  East South Central 65,473 79.4 17,018 20.6  
  West North Central 86,170 80.4 21,001 19.6  
  West South Central 73,527 78.4 20,310 21.6  
  Mountain 43,581 80.3 10,718 19.7  
  Pacific 133,171 82.7 27,920 17.3  
Facility Type     <.0001 
  Community Cancer Program 112,520 74.4 38,779 25.6  
  Comprehensive Community Cancer 
Program 
544,256 
79.2 
142,559 
20.8 
 
  Academic/Research Program 290,117 78.9 77,469 21.1  
  Integrated Network Cancer Program 127,254 81.2 29,463 18.8  
Facility Volume     <.0001 
  Low (<71) 198,466 73.2 72,653 26.8  
  Low/Medium (71-112) 211,027 77.8 60,196 22.2  
  Medium (113-161) 217,306 79.8 55,107 20.2  
  Medium/High (162-240) 222,690 81.3 51,264 18.7  
  High (>240) 224,658 82.1 49,050 17.9  
a Percentages are based on row percentages. b Row percentages may not equal 100% due 
to rounding. * Chi-square test is used to test for statistical significance at the p ≤0.05 
level. ** Comorbidity index is based on Charlson-Deyo score. Column percentages may 
not equal 100% due to rounding. *** Tumor characteristics are based on the ASCO. †The 
p-value for great circle distance is derived from a t-test. Abbreviations: SE = Standard 
Error, HS = High School.  
 
   
 
5
2
 
Table 4.3 Individual- and facility-level factors predicting the odds of needle biopsy in 2004 – 2015 
 Model 1 Model 2 Model 3a,b 
Age    
  40-49 Ref Ref Ref 
  50-59  1.114 
(1.099, 1.130) 
1.115 
(1.099, 1.130) 
  60-69  1.201 
(1.182, 1.219) 
1.200 
(1.182, 1.219) 
  70-79  1.195 
(1.172, 1.217) 
1.194 
(1.172, 1.217) 
  80+  0.975 
(0.955, 0.996) 
0.975 
(0.955, 0.996) 
Race/Ethnicity    
  White Ref Ref Ref 
  Black  1.033 
(1.016, 1.050) 
1.035 
(1.018, 1.052) 
  Hispanic  1.047 
(1.021, 1.074) 
1.047 
(1.021, 1.074) 
  Other  1.033 
(1.008, 1.058) 
1.033 
(1.008, 1.058) 
Insurance Status    
  Private Insurance/Managed Care Ref Ref Ref 
  Not Insured/Insurance Status 
Unknown 
 1.039 
(1.010, 1.069) 
1.040 
(1.010, 1.070) 
  Medicaid  1.052 
(1.028, 1.077) 
1.056 
(1.031, 1.081) 
  Medicare  0.977 
(0.964, 0.991) 
0.979 
(0.965, 0.993) 
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  Other Government  1.026 
(0.973, 1.083) 
1.027 
(0.973, 1.084) 
Urban/Rural Residence    
  1 million+ Ref Ref Ref 
  250,000-1 million  0.956 
(0.930, 0.983) 
0.956 
(0.930, 0.983) 
  <250,000  0.893 
(0.865, 0.922) 
0.894 
(0.866, 0.923) 
  20,000+, adjacent to metro area  0.858 
(0.828 0.889) 
0.861 
(0.831, 0.892) 
  20,000+, not adjacent to metro 
area 
 0.860 
(0.809, 0.905) 
0.866 
(0.814, 0.922) 
  2,500-19,999, adjacent to metro 
area 
 0.897 
(0.868, 0.928) 
0.899 
(0.869, 0.929) 
  2,500-19,999, not adjacent to 
metro area 
 0.872 
(0.831, 0.915) 
0.875 
(0.834, 0.918) 
  <2,500, adjacent to metro area  0.882 
(0.830, 0.939) 
0.885 
(0.832, 0.942) 
  <2,500, not adjacent to metro area  0.886 
(0.829, 0.946) 
0.891 
(0.834, 0.952) 
Comorbidity Index    
  0 Ref Ref Ref 
  1  0.914 
(0.902, 0.927) 
0.915 
(0.902, 0.927) 
  2  0.890 
(0.863, 0.917) 
0.890 
(0.864, 0.918) 
  3+  0.852 
(0.803, 0.903) 
0.851 
(0.802, 0.902) 
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Year of Diagnosis    
  2004 Ref Ref Ref 
  2005  1.178 
(1.154, 1.201) 
1.177 
(1.154, 1.201) 
  2006  1.383 
(1.356, 1.411) 
1.381 
(1.353, 1.408) 
  2007  1.553 
(1.522, 1.585) 
1.547 
(1.516, 1.578) 
  2008  1.624 
(1.591, 1.658) 
1.616 
(1.583, 1.650) 
  2009  2.070 
(2.026, 2.115) 
2.045 
(2.002, 2.090) 
  2010  2.662 
(2.602, 2.723) 
2.638 
(2.579, 2.669) 
  2011  3.437 
(3.537, 3.518) 
3.387 
(3.308, 3.468) 
  2012  4.025 
(3.929, 4.123) 
3.965 
(3.870, 4.061) 
  2013  4.321 
(4.217, 4.427) 
4.261 
(4.159, 4.366) 
  2014  4.837 
(4.719, 4.958) 
4.735 
(4.619, 4.854) 
  2015  4.737 
(4.622, 4.856) 
4.626 
(4.513, 4.743) 
Tumor Size/Extension    
  T0 Ref Ref Ref 
  Ti  4.416 
(4.183, 4.661) 
4.443 
(4.209, 4.691) 
  T1  6.756 
(6.378, 7.157) 
6.813 
(6.431, 7.217) 
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  T2  9.288 
(8.744, 9.866) 
9.374 
(8.824, 9.957) 
  T3  10.572 
(9.856, 11.341) 
10.671 
(9.947, 11.450) 
  T4  8.132 
(7.522, 8.792) 
8.244 
(7.625, 8.913) 
  Unknown  4.280 
(4.057, 4.515) 
4.325 
(4.100, 4.563) 
Lymph Node Metastasis    
  N0 Ref Ref Ref 
  N1  1.382 
(1.343, 1.422) 
1.384 
(1.345, 1.424) 
  N2  1.126 
(1.060, 1.197) 
1.128 
(1.061, 1.199) 
  N3  1.063 
(0.983, 1.151) 
1.064 
(0.984, 1.152) 
  Unknown  1.640 
(1.611, 1.677) 
1.642 
(1.610, 1.675) 
Clinical Stage Group    
  0 Ref Ref Ref 
  I  0.545 
(0.522, 0.568) 
0.544 
(0.521, 0.567) 
  II  0.480 
(0.458, 0.503) 
0.479 
(0.457, 0.502) 
  III  0.468 
(0.437, 0.501) 
0.467 
(0.437, 0.499) 
  Unknown  0.340 
(0.329, 0.351) 
0.339 
(0.328, 0.351) 
Behavior    
  In situ Ref Ref Ref 
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  Invasive  3.109 
(3.057, 3.162) 
3.110 
(3.057, 3.163) 
Great Circle Distance    
    0.999580 
(0.999513, 0.999650) 
0.999570 
(0.999563, 0.999576) 
Hospital Census Region    
  New England Ref Ref Ref 
  Middle Atlantic   0.678 
(0.548, 0.840) 
  South Atlantic   0.884 
(0.723, 1.081) 
  East North Central   1.016 
(0.831, 1.242) 
  East South Central   0.926 
(0.723, 1.186) 
  West North Central   1.114 
(0.877, 1.414) 
  West South Central   0.865 
(0.685, 1.091) 
  Mountain   1.022 
(0.776, 1.346) 
  Pacific   1.176 
(0.946, 1.462) 
Facility Type    
  Academic/Research Program Ref Ref Ref 
  Community Cancer Program   0.913 
(0.794, 1.051) 
  Comprehensive Community 
Cancer Program 
  1.014 
(0.890, 1.154) 
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  Integrated Network Cancer 
Program 
  1.041 
(0.876, 1.235) 
Facility Volume    
  Low Ref Ref Ref 
  Low/Medium   1.281 
(1.253, 1.309) 
  Medium   1.440 
(1.401, 1.479) 
  Medium/High   1.538 
(1.489, 1.589) 
  High   1.506 
(1.446, 1.568) 
aOnly variables significant on multivariable analysis are shown. bROC AUC = 0.7838.
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Table 4.4 Random effects covariance estimates from the NCDB, 2004 – 2015 
 Model 1 Model 2 Model 3 
Random Effect Type Intercept Intercept Intercept 
Covariance Estimate 0.6795 0.7642 0.6785 
Standard Error 0.02783 0.03130 0.02777 
95% Confidence Interval (0.628, 0.738) (0.706, 0.830) (0.627, 0.736) 
Statistical Test Chi-square test of 
covariance 
Parameter = 0 
Chi-square test 
of covariance 
Parameter = 0 
Chi-square test 
of covariance 
Parameter = 0 
Test Statistic 107043 109219 96249 
Degrees of Freedom 1 1 1 
P-Value <.0001 <.0001 <.0001 
AUC - - 0.7838 
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CHAPTER 5 
CONCLUSION 
 
Summary of Results 
 In summary, patients who had an increased likelihood of receiving guideline-
concordant care were Hispanic, 60-69 years of age, had a comorbidity index score of 0, 
and had health insurance coverage through Medicaid. Patients who lived in metropolitan 
areas of 1 million people or more were more likely to receive guideline concordant breast 
cancer care through needle biopsy as compared with patients from urban and rural areas. 
Additionally, patients who received a diagnosis at a facility in New England were more 
likely to receive guideline-concordant care as compared to the 8 other U.S. census 
regions examined in this study. Patients who were diagnosed at high case volume 
facilities were more likely to receive guideline concordant treatment as compared to 
patients who were diagnosed at low case volume facilities.   
Significance of Findings 
 The results from this study support findings from previous research on needle 
biopsy utilization from nationally-sourced datasets (23,60). Compared to the Williams et 
al. study, which was published in 2011 using data obtained from the NCDB PUF, our 
study has more pertinent data that builds a more accurate representation of patients who 
receive guideline concordant care through needle biopsy. Findings from this study can 
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assist in the exploration of individual-level factors, specifically tumor characteristics, as 
predictors of guideline-concordant breast cancer care. 
 In our study, needle biopsy utilization increased rapidly from 2004-2012, and 
began to level off from 2013-2015. This research can be used to directly to monitor and 
benchmark guideline concordance progression through time. The results of this study can 
also inform future policies an attempt to reduce health disparities among patients with 
breast cancer by providing the most vulnerable groups with the tools and resources they 
need to access quality care.  
Further Research 
 Further research should examine the complete association between tumor 
characteristics and guideline-concordant breast cancer care. While our study explored 
associations in a few of these characteristics, the exact mechanisms through which tumor 
characteristics impact guideline concordant care is unknown. Inequalities may drive the 
differences in effect measures of tumor characteristics in relation to needle biopsy 
receipt, but having access to individualized patient data regarding income and education 
could help obtain answers to the knowledge gaps in tumor characteristics as they relate to 
guideline concordance.
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